98%
921
2 minutes
20
Transmembrane L1 cell adhesion molecule (L1CAM) is widely used as a marker to enrich for neuron-derived extracellular vesicles (EVs), especially in plasma. However, this approach lacks sufficient robust validation. This study aimed to assess whether human biofluids are indeed enriched for EVs, particularly neuron-derived EVs, by L1CAM immunoaffinity, utilizing multiple sources (plasma, CSF, conditioned media from iPSC-derived neurons [iNCM]) and different methods (mass spectrometry [MS], nanoparticle tracking analysis [NTA]). Following a systematic multi-step validation approach, we confirmed isolation of generic EV populations using size-exclusion chromatography (SEC) and polymer-aided precipitation (PPT)-two most commonly applied EV isolation methods-from all sources. Neurofilament light (NfL) was detected in both CSF and blood-derived EVs, indicating their neuronal origin. However, L1CAM immunoprecipitation did not yield enrichment of L1CAM in EV fractions. Instead, it was predominantly found in its free-floating form. Additionally, MS-based proteomic analysis of CSF-derived EVs also did not show L1CAM enrichment. Our study validates EV isolation from diverse biofluid sources by several isolation approaches and confirms that some EV subpopulations in human biofluids are of neuronal origin. Thorough testing across multiple sources by different orthogonal methods, however, does not support L1CAM as a marker to reliably enrich for a specific subpopulation of EVs, particularly of neuronal origin.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289729 | PMC |
http://dx.doi.org/10.1007/s12035-025-04909-2 | DOI Listing |
Sleep Med Clin
September 2025
Centre for Neurology, Academic Specialist Centre, Stockholm Health Services, Solnavägen 2, 11365 Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; Department of Neurology, Karolinska University Hospital, Bioclinicum J5:20, Stockholm 17164, Swede
Parkinson's disease is a neurodegenerative disorder with an increasing prevalence worldwide. The development of disease-modifying therapies remains a critical priority; however, early intervention is limited by the paucity of robust biomarkers for the prodromal stage. Sleep disturbances-particularly isolated rapid eye movement sleep behavior disorder (iRBD)-are emerging as key clinical markers of prodromal synucleinopathy, offering opportunities for early detection and risk stratification.
View Article and Find Full Text PDFNat Commun
August 2025
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer's disease (AD). However, previous studies show that CSF t-tau correlates strongly with synaptic dysfunction/degeneration biomarkers like neurogranin (Ng) and synaptosomal-associated protein 25 (SNAP25). Here, we compare the association between CSF t-tau and synaptic degeneration and axonal/neuronal degeneration biomarkers in cognitively unimpaired and impaired groups from two independent cohorts.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Department of Biosciences Biotechnologies and Environment, University of Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.
Mitochondrial oxidative stress and neuroinflammation are involved in the onset and progression of Alzheimer's disease (AD). Novel reliable, circulating biomarkers related to these processes were searched in cerebrospinal fluid (CSF) and plasma samples. Paired CSF and plasma samples from 20 subjective memory complaints (SMC) subjects, 20 mild cognitive impairment (MCI) due to AD subjects, and 20 Alzheimer's dementia (ADd) patients were analyzed.
View Article and Find Full Text PDFMed Oncol
August 2025
Department of Biochemistry and Molecular Biology, Faculty of Pharmacy for Girls, Al-Azhar University, Cairo, Egypt.
Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men, with progression to castration-resistant and metastatic disease driven largely by therapeutic resistance. While numerous reviews have cataloged dysregulated microRNAs (miRNAs) in prostate cancer, this review offers a novel, mechanism-centered synthesis focused specifically on miRNA-mediated resistance pathways across standard treatment modalities-including androgen deprivation therapy (ADT), enzalutamide, docetaxel, and radiotherapy. Rather than providing a broad survey of miRNA functions, we prioritize miRNAs with robust experimental validation in PCa (e.
View Article and Find Full Text PDFSci Rep
August 2025
Neurocom, CICA - Centro Interdisciplinar de Química e Bioloxía, Universidade da Coruña (UDC), Campus de Elviña, A Coruña, Spain.
Transcranial static magnetic stimulation has shown the capacity to decrease systematically the cortical excitability in the treatment of epilepsy. Nevertheless, the application of these therapies to non-focal epilepsies is limited. This paper investigates on the numerical evaluation of promising strategies based on the application of static magnetic fields with multiple magnets on children.
View Article and Find Full Text PDF